These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15266252)

  • 1. Psychopharmacology in the New York Times.
    Kramer TA
    MedGenMed; 2004 Jun; 6(2):26. PubMed ID: 15266252
    [No Abstract]   [Full Text] [Related]  

  • 2. Are paroxetine, fluoxetine, and sertraline equally effective for depression?
    Straton JB; Cronholm P
    J Fam Pract; 2002 Mar; 51(3):285. PubMed ID: 11978244
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical practice guidelines for depression in young people.
    Jureidini JN; Tonkin AL
    Med J Aust; 2003 Mar; 178(6):300; author reply 300-2. PubMed ID: 12633493
    [No Abstract]   [Full Text] [Related]  

  • 4. Selective serotonin reuptake inhibitors plus pindolol. The REEP.
    Bordet R; Thomas P; Dupuis B
    Lancet; 1997 Jul; 350(9073):289. PubMed ID: 9242816
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of SSRIs in "very old" depressed nursing home residents.
    Trappler B; Cohen CI
    Am J Geriatr Psychiatry; 1998; 6(1):83-9. PubMed ID: 9469218
    [No Abstract]   [Full Text] [Related]  

  • 6. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression.
    O'Connor M; Silver H
    J Clin Psychopharmacol; 1998 Feb; 18(1):89-91. PubMed ID: 9472852
    [No Abstract]   [Full Text] [Related]  

  • 7. SSRIs and tamoxifen. Why condemn fluoxetine?
    Jenkinson ML
    BMJ; 2010 Mar; 340():c1319. PubMed ID: 20219794
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder.
    Bakish D; Cavazzoni P; Chudzik J; Ravindran A; Hrdina PD
    Biol Psychiatry; 1997 Jan; 41(2):184-90. PubMed ID: 9018388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
    Polsky D; Onesirosan P; Bauer MS; Glick HA
    J Clin Psychiatry; 2002 Feb; 63(2):156-64. PubMed ID: 11874218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychopharmacologic treatment of adolescent depression.
    Lynch A; Glod CA; Fitzgerald F
    Arch Psychiatr Nurs; 2001 Feb; 15(1):41-7. PubMed ID: 11172238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
    Fava M; Judge R; Hoog SL; Nilsson ME; Koke SC
    J Clin Psychiatry; 2000 Nov; 61(11):863-7. PubMed ID: 11105740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin reuptake inhibitor-related extrapyramidal side effects in two patients with cerebral palsy.
    Rone LA; Ferrando SJ
    Psychosomatics; 1996; 37(2):165-6. PubMed ID: 8742546
    [No Abstract]   [Full Text] [Related]  

  • 13. Heterogeneity of SSRI response.
    Salzman C
    Harv Rev Psychiatry; 1996; 4(4):215-7. PubMed ID: 9384996
    [No Abstract]   [Full Text] [Related]  

  • 14. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study.
    Henry ME; Moore CM; Kaufman MJ; Michelson D; Schmidt ME; Stoddard E; Vuckevic AJ; Berreira PJ; Cohen BM; Renshaw PF
    Am J Psychiatry; 2000 Sep; 157(9):1506-8. PubMed ID: 10964871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of personality by serotonergic intervention.
    Balon R
    Am J Psychiatry; 1999 Jun; 156(6):985. PubMed ID: 10360169
    [No Abstract]   [Full Text] [Related]  

  • 16. Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents.
    Garland EJ; Baerg EA
    J Child Adolesc Psychopharmacol; 2001; 11(2):181-6. PubMed ID: 11436958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR; Mills JA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
    [No Abstract]   [Full Text] [Related]  

  • 18. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
    J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of selective serotonin reuptake inhibitors in childhood depression.
    Wohlfarth T; Lekkerkerker F; van Zwieten B
    Lancet; 2004 Aug 21-27; 364(9435):659-60; author reply 661. PubMed ID: 15325820
    [No Abstract]   [Full Text] [Related]  

  • 20. Paroxetine in major depression.
    Jureidini J; Tonkin A
    J Am Acad Child Adolesc Psychiatry; 2003 May; 42(5):514; author reply 514-5. PubMed ID: 12707552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.